Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. 1.7 million new HIV infections were reported globally in 2019 and 38 million people were living with HIV, according to the World Health Organization. "The market will infer that GSK and ViiV are left out in the cold here, supporting our long-standing concerns over the longer term outlook for GSK's HIV franchise," Citi analyst Andrew Baum said.
Andrew Baum is a man.
( z0 man :domain ( z1 person :name ( z2 name :op "Andrew" :op "Baum" ) ) )
(z0 / man
    :domain (z1 / person
                :name (z2 / name
                          :op1 "Andrew"
                          :op2 "Baum")))
Andrew Baum is a man .
z1 :name z2
z2 :op1 0
z2 :op2 1
z0 :domain z1